DDInter1380 DDInter1628
Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Palifermin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fludarabine
Fludarabine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Palifermin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fludarabine
Fludarabine {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Palifermin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bexarotene
Bexarotene {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Palifermin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinblastine
Vinblastine {u} (Compound) upregulates {v} (Gene) DAPK3
DAPK3 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Palifermin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cisplatin
Cisplatin {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Palifermin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Ponatinib {u} (Compound) downregulates {v} (Gene) DUSP4
DUSP4 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Palifermin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinblastine
Vinblastine {u} (Compound) upregulates {v} (Gene) DUSP4
DUSP4 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Palifermin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cladribine
Cladribine {u} (Compound) downregulates {v} (Gene) PLK1
PLK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Palifermin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Ponatinib {u} (Compound) upregulates {v} (Gene) SLC35A1
SLC35A1 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Palifermin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinblastine
Vinblastine {u} (Compound) downregulates {v} (Gene) KIAA0907
KIAA0907 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine (Compound) upregulates DAPK3 (Gene) and DAPK3 (Gene) is bound by Ruxolitinib (Compound)
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib (Compound) downregulates DUSP4 (Gene) and DUSP4 (Gene) is upregulated by Ruxolitinib (Compound)
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine (Compound) upregulates DUSP4 (Gene) and DUSP4 (Gene) is upregulated by Ruxolitinib (Compound)
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Cladribine and Cladribine (Compound) downregulates PLK1 (Gene) and PLK1 (Gene) is bound by Ruxolitinib (Compound)
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib (Compound) upregulates SLC35A1 (Gene) and SLC35A1 (Gene) is downregulated by Ruxolitinib (Compound)
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine (Compound) downregulates KIAA0907 (Gene) and KIAA0907 (Gene) is downregulated by Ruxolitinib (Compound)